The Prognostic Value of HER1 R497K in the Management of Patients with Breast Cancer

Introduction: Breast cancer is the most common cancer among the women. Despite the advances in the diagnosis of metastatic cancers, there are still many challenges. Hence, there is a need to use a sensitive, fast and cheap method for diagnosis. Tumor markers are one of the methods that are used extensively for this purpose. Despite extensive efforts to identify novel prognostic and predictive clinical biomarkers, a very small number of markers have been reported as risk stratification biomarkers (e.g., BRCA1/2 and HER2). The substitution of arginine with lysine in codon 497 of HER1 497 has been suggested as a potential marker in breast cancer. This study attempted to explore the association between HER1 497 gene polymorphisms with pathological and clinical information of breast cancer patients. Methods: 110 breast cancer patients were recruited in this study. Genomic DNA extraction and genotyping were performed using Taqman-PCR and sequencing, respectively. The association between this genetic variant with breast cancer risk and pathological information of patients was evaluated. Results: Findings showed that 9.43% of cases had AA genotype, while these frequencies inAC and CC genotypes were 77.35% and 13.20%, respectively. Moreover, we assessed that 78.4% of breast cancer patients with M0 had AA+AC genotypes, while 21.6% of CC cases had M0 status. Furthermore, 22.7% of these cases with CC genotype had N0/1. We observed that most patients with CC genotype had lower HER2 expression. Conclusions: Our study indicated the potential association of CC genotype of HER1 497 with the prognosis of patients with breast cancer.